SCHEMBL481365

SCHEMBL481365

COC(=O)c1ccc(Cc2ccc(COc3ccc(C(C)=O)c(O)c3-c3cccs3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
RAB9A P51151 5/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
NPC1 O15118 2/20 0.41
TP53 P04637 1/20 0.41
ATM Q13315 1/20 0.41
TNFRSF1A P19438 4/20 0.41
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
CTSK P43235 1/20 0.37
GRM2 Q14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480981 0.94 MAPT (0.41) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19
SCHEMBL481518 0.92 MAPT (0.43) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19
SCHEMBL481244 0.90 MAPT (0.48) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19
SCHEMBL480912 0.87 MRGPRX4 (0.43) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19
SCHEMBL481088 0.84 MAPT (0.47) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19
SCHEMBL481174 0.84 MAPT (0.44) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19
SCHEMBL481192 0.79 MRGPRX4 (0.48) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19
SCHEMBL481184 0.78 GRM2 (0.58) CYP2C19GRM2CYSLTR1
SCHEMBL481373 0.77 MAPT (0.41) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19
SCHEMBL481077 0.76 SMN1; SMN2 (0.43) MAPTSMN1; SMN2L3MBTL1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 MAPT 3525/4885SMN1; SMN2 4205/4885L3MBTL1 4883/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 MAPT 2945/4885SMN1; SMN2 3201/4885L3MBTL1 4883/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 MAPT 2945/4885SMN1; SMN2 3201/4885L3MBTL1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.